Mark Pollack to Delayed-Action Preparations
This is a "connection" page, showing publications Mark Pollack has written about Delayed-Action Preparations.
Connection Strength
0.499
-
Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008 Mar; 69(3):400-5.
Score: 0.077
-
Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008 May; 197(4):675-81.
Score: 0.077
-
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
Score: 0.074
-
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
Score: 0.071
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
Score: 0.060
-
Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003 Jun; 23(3):250-9.
Score: 0.056
-
Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003; 37(4):66-72.
Score: 0.054
-
Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Curr Med Res Opin. 2007 Jun; 23(6):1431-43.
Score: 0.018
-
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000 Jun; 157(6):968-74.
Score: 0.011